CA-CROWN-BIOSCIENCE
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced a strategic partnership with Clinical Trial & Consulting Services (CTI), a renowned global full-spectrum research service provider, to bolster oncology-focused consulting services. This collaboration unites decades of expertise from both organizations in oncology drug discovery and development, leveraging Crown Bioscience’s preclinical and translational models and CTI’s well-established track record in the clinical and regulatory space.
Customers will benefit from combined expert guidance, supporting the transition of oncology compounds from discovery through early-phase clinical trials more rapidly and effectively. This alliance aims to determine the optimal and most expeditious path to the clinic, ensure long-term drug development success and growth, and accelerate the delivery of superior oncology therapeutics to patients.
From today, customers can access consulting services to ensure an integrated drug development approach, including:
- Strategic preclinical development planning
- Study data analysis, interpretation and advice
- Regulatory guidance
- De novo assay development
- Grant review
Alex Slater, Senior Vice President of Commercial, commented: ‘’Crown Bioscience has an established reputation for exceeding the typical services offered by a regular CRO. This initiative unites deep-seated expertise spanning all phases of drug development, marking a pivotal step towards delivering a true translational offer to our clients.’’
Ryan Gifford, Vice President of Global Laboratory Services, Business Development, shares: ‘’We are delighted to collaborate with Crown Bioscience and view this as a valuable synergy. Crown Bioscience’s leadership in early-phase oncology research and suite of preclinical services complement CTI’s broad spectrum of capabilities. Together, we can offer enhanced support to our oncology clients and deepen our commitment to advancing cancer research.’’
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) dedicated to improving human health through partnering with biotech and pharmaceutical companies that drive the discovery and development of oncology drugs. We exclusively offer preclinical tumor organoid services using the well-established Hubrecht Organoid Technology, with over 600 organoid models available spanning 22 cancer indications. In addition, we have developed the world’s largest commercially available PDX collection. Further committed to personalized medicine, our subsidiary, Indivumed Services, maintains an extensive biobank of liquid and tissue human biospecimens. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 12 facilities across the US, Europe, and Asia. For more information, please visit www.crownbio.com
About CTI Clinical Trial & Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, research service organization, delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides clinical and disease area expertise with nuanced regulator support. CTI also offers a fully integrated multi-specialty clinical research site and complete global laboratory services. Now in its third decade, CTI is one of the 20 largest contract research organizations in the world, with associates in more than 60 countries across six continents. CTI is headquartered in the Greater Cincinnati area, with operations across North America, Europe, Latin America, MEA, and Asia-Pacific. For more information, visit www.ctifacts.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821624556/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Belkin styrker beskyttelsen af hverdagsenheder med en ny serie skærmbeskyttere og et Wear & Tear-program4.1.2026 18:00:00 CET | Pressemeddelelse
Belkin lancerer syv nye skærmbeskyttere, der er udviklet med proprietær Nano-Titan-teknologi for øget styrke mod daglige fald og ridser Et Wear and Tear-program skaber ro i sindet for forbrugere, der ønsker at udskifte deres produkter Forbrugerne kan nu personalisere deres skærmbeskyttere med Screen Skinz Belkin, et førende mærke inden for forbrugerelektronik i over 40 år, annoncerer i dag en ny klasse af løsninger til skærmbeskyttelse, et strategisk partnerskab og et helt nyt wear-and-tear-program, der styrker virksomhedens engagement i at beskytte enheder og give forbrugerne tryghed. Lanceringen omfatter syv nye skærmbeskyttere, et partnerskab med ScreenSkinz vedrørende personalisering, og et program til udskiftning af skærmbeskyttere beregnet til at give brugerne varig ro i sindet og sikre, at de produkter, de elsker, forbliver trygge, sikre og i den bedste form. Mød ScreenForce Titan-serien: Det ultimative inden for fuldskærmsbeskyttelse Titan SmartShield Titan SmartShield fungerer
Belkin præsenterer næste generation af opladere, strømtilbehør til gaming og meget mere på CES 20264.1.2026 18:00:00 CET | Pressemeddelelse
Belkin lancerer nye trådløse Qi2-opladere, powerbanks med høj kapacitet, kraftfulde hubs samt et opladningsetui til Nintendo Switch 2, der får debut på CES 2026 Belkin, et førende mærke inden for forbrugerelektronik i over 40 år, annoncerede i dag en ny serie af tilbehør, der er designet til at styrke, beskytte og forbedre den måde, folk arbejder, leger og er forbundet på. Den nye kollektion, som debuterer på CES 2026, omfatter avancerede powerbanks, Qi2 25 W trådløse opladere, en trådløs HDMI-dongle til problemfri deling af indhold og et opladningsetui af næste generation til Nintendo Switch 2. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260104854623/da/ Belkin unveils new products at CES 2026 Gaming Charging Case Pro til Nintendo Switch 2 (model ENA003) Udviklet til den ultimative gamingoplevelse på farten leverer Pro-etuiet strøm, beskyttelse og mobilitet samlet i én førsteklasses løsning. En udtagelig powerbank på 1
SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement4.1.2026 16:13:00 CET | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order governing the Company’s board composition and corporate actions pending trial, and announced the engagement of Zhonghua Certified Public Accountants LLP (“Zhonghua”), an affiliate of the global accounting network UHY International, as the Company’s independent auditor and registered public accounting firm. Update on Antigua High Court Order Further to the order issued by the Antigua High Court (the “Court”) previously disclosed by the Company in a press release dated December 17, 2025, the Court has updated its order to provide that directors Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Dr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Weidong Yin (collectively, the “Board”), will comprise the Board of the Company until the trial liste
Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report4.1.2026 16:00:00 CET | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Company was not in compliance with Nasdaq’s Listing Rule 5250(c)(2) since the Company did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025. As previously disclosed, the Company received a delisting determination letter (the “Staff Determination”) from Nasdaq in November 2025. The Company requested a hearing before the Nasdaq Hearings Panel to appeal the Staff Determination on November 19, 2025. Nasdaq has informed the Company that the Nasdaq Hearings Panel will also consider the matter addressed in the Notification Letter at a hearing scheduled for January 8, 2026 at which the Company has been invited to present
Consumer Tech Growth to Reset in 2026 as Demand Shifts to Europe and MEA4.1.2026 13:00:00 CET | Press release
Global market to flatten (-0.4% YoY) in 2026; Small Domestic Appliances and IT drive growth, as Telecom and Consumer Electronics demand softens NielsenIQ (NYSE:NIQ), a global leader in consumer intelligence, today released its 2026 Consumer Tech & Durable Goods (T&D) market outlook. In collaboration with the Consumer Technology Association (CTA), NIQ expects T&D global sales to level off in 2026 after a strong 2025. The sector is set to finish 2025 at roughly $1.3 trillion USD, up 3% from 2024, while 2026 overall sales value is projected to hold steady at an estimated -0.4% year over year (YoY). While the global picture looks flat, the real story lies in the differences in regional and sector performance. Consumers overall remain careful with their spending and are prioritizing value for money—with a focus on products that offer enhanced performance, convenience, energy-saving, and/or durability. Brands and retailers that align pricing, innovation, and experience to region- and categor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom